Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.

Show other versions (1)

Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive. We conducted a systematic review and meta-analysis of randomiz...

Full description

Bibliographic Details
Main Authors:	Jian Fu, Yi Gao, Li Shi
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0267647

Similar Items

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
by: Jian Fu, et al.
Published: (2022-01-01)

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A meta-analysis
by: Saad Khalid, et al.
Published: (2024-04-01)

Comparing efficacy of Rifaximin plus Lactulose vs. Lactulose alone in treating Hepatic Encephalopathy
by: Tanveer Hussain, et al.
Published: (2020-12-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
by: Ming-Wei Wang, et al.
Published: (2023-03-01)

A comparative study to determine the short-term mortality and clinical improvement in hepatic encephalopathy using either rifaximin and or lactulose
by: Uttam Biswas, et al.
Published: (2021-03-01)

The effect of rifaximin and lactulose treatments to chronic hepatic encephalopathy rats: An [18F]PBR146 in‐vivo neuroinflammation imaging study
by: Xiang Kong, et al.
Published: (2024-07-01)

Rifaximin in the treatment of hepatic encephalopathy
by: Iadevaia MD, et al.
Published: (2011-12-01)

Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis
by: Gilles Jadd Hoilat, et al.
Published: (2021-10-01)

Efficacy Comparison of Nitazoxanide Combined with Lactulose versus Lactulose Monotherapy in Managing Overt Hepatic Encephalopathy
by: Taimoor Hafeez Janjua, et al.
Published: (2025-01-01)

Incidence of Hepatic Encephalopathy in Patients with Spontaneous Bacterial Peritonitis Using Rifaximin and Lactulose: A Study at a Tertiary Care Hospital in Rawalpindi
by: Muhammad Saad Aziz, et al.
Published: (2024-08-01)

Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis
by: Ahmed Elmoursi, et al.
Published: (2023-06-01)

Rifaximin as treatment for hepatic encephalopathy: Some considerations
by: Lorenzo Ridola, et al.
Published: (2013-01-01)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
by: Dong Wu, et al.
Published: (2013-01-01)

Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose
by: Praveen Sharma, et al.
Published: (2011-01-01)

Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy
by: Ahmad Shavakhi, et al.
Published: (2014-01-01)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
by: Kimer N, et al.
Published: (2014-03-01)

Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy
by: C.E. Coronel-Castillo, et al.
Published: (2020-01-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
by: Jasmohan S Bajaj, et al.
Published: (2013-01-01)

Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy
by: Shireen Ahmed, et al.
Published: (2018-01-01)

Lactulose enhances neuroplasticity to improve cognitive function in early hepatic encephalopathy
by: Yang, N, et al.
Published: (2015)

Lactulose enhances neuroplasticity to improve cognitive function in early hepatic encephalopathy
by: Nan Yang, et al.
Published: (2015-01-01)

Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction
by: Praveen Sharma, et al.
Published: (2012-01-01)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
by: Masato Nakai, et al.
Published: (2022-01-01)

Role of Rifaximin in Prevention of Recurrent Hepatic Encephalopathy in Chronic Liver Disease
by: Sahar Farzand, et al.
Published: (2020-12-01)

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
by: Guihua Fang, et al.
Published: (2024-03-01)

RIFAXIMIN EFFECTIVENESS IN PREVENTING THE RECURRENCE OF HEPATIC ENCEPHALOPATHY AMONG PATIENTS WITH LIVER CIRRHOSIS
by: Muhammad Zulqurnain Saleem, et al.
Published: (2021-08-01)

Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy
by: Francisco Idalsoaga, et al.
Published: (2024-05-01)

Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial
by: Mohammadreza Naderian, et al.
Published: (2017-01-01)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
by: Xiaojun Zhuang, et al.
Published: (2020-06-01)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
by: Yoshimi Yukawa‐Muto, et al.
Published: (2022-08-01)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
by: Alba Mangas-Losada, et al.
Published: (2019-08-01)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
by: Xiao Yu, et al.
Published: (2022-01-01)

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
by: M Kramer, et al.
Published: (2020-02-01)

Rifaximin alone vs combination with norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis with hepatic encephalopathy: randomized controlled trial
by: Tarana Gupta, et al.
Published: (2024-09-01)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
by: Rosalie C. Oey, et al.
Published: (2019-06-01)

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy
by: Igor G. Bakulin, et al.
Published: (2023-10-01)

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy
by: Valentina Perrone, et al.
Published: (2025-01-01)